Oral and Topical Centella asiatica in Type 2 Diabetes Mellitus Patients with Dry Skin: A Three-Arm Prospective Randomized Double-Blind Controlled Trial
Table 2
SRRC, SCap, CML, IL-1α, and SOD activity based on the intervention group (N = 159).
Variable
CAo + CAt (n = 53)
Plo + CAt (n = 53)
Plo + Plt (n = 53)
value
SRRC
D 1
0.07
Median (min–max)
4 (3–10)
4 (3–8)
5 (3–8)
D 15
0.48
Median (min–max)
2 (0–6)
3 (0–7)
3 (0–7)
D 29
0.71
Median (min–max)
2 (0–6)
2 (0–7)
2 (0–6)
SCap (AU)
D 1
0.34
Median (min–max)
27.7 (10.4–36.4)
25.4 (10.7–37.8)
26.2 (12.1–46)
D 15
0.38
Median (min–max)
37.6 (14.5–61.6)
35.9 (12.5–61)
35 (16.1–59.9)
D 29
0.39
Median (min–max)
43.5 (14.5–65.9)
44.6 (13.1–64)
38.5 (16.9–63.7)
CML (pg/mg protein)
D 1
0.79
Median (min–max)
87.2 (20.12–14559.42)
77.2 (4.1–385.7)
93.9 (14–407.8)
D 29
0.41
Median (min–max)
119.8 (24.2–615.9)
119.4 (25.2–1731.4)
104.8 (22–748.1)
IL-1α (pg/mg protein)
D 1
0.60
Median (min–max)
16.5 (2.9–167.3)
16 (2.1–110.5)
17.6 (4.4–114.6)
D 29
0.68
Median (min–max)
19.7 (3.2–167.3)
18.2 (4.9–69.6)
17.6 (4.9–114.5)
SOD (U/mg protein)
D 1
0.31
Median (min–max)
4.6 (0.3–59.4)
3.4 (0.3–41.5)
3.9 (0.2–35)
D 29
0.07
Median (min–max)
5.9 (1–59.4)
4.3 (0.2–18.7)
4.9 (0.1–23.6)
Kruskal–Wallis test was performed to assess the difference.